May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The effect of novel immuno–modulatory and anti–angiogenic glycodendrimers in a rabbit model of glaucoma surgery
E. Jones; K. Mireskandari; A. Mead; S. Thomas; P. Luthert; S. Brocchini; S. Shaunak; P.T. Khaw
Author Affiliations & Notes
  • E. Jones
    Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
  • K. Mireskandari
    Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
  • A. Mead
    Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
  • S. Thomas
    Faculty of Medicine, Imperial College, London, United Kingdom
  • P. Luthert
    Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
  • S. Brocchini
    School of Pharmacy, University of London, London, United Kingdom
  • S. Shaunak
    Faculty of Medicine, Imperial College, London, United Kingdom
  • P.T. Khaw
    Pathology, Institute of Ophthalmology, University College London, London, United Kingdom
    Glaucoma, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  E. Jones, None; K. Mireskandari, None; A. Mead, None; S. Thomas, None; P. Luthert, None; S. Brocchini, Polytherics F; S. Shaunak, Polytherics F; P.T. Khaw, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1053. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The effect of novel immuno–modulatory and anti–angiogenic glycodendrimers in a rabbit model of glaucoma surgery
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      E. Jones, K. Mireskandari, A. Mead, S. Thomas, P. Luthert, S. Brocchini, S. Shaunak, P.T. Khaw; The effect of novel immuno–modulatory and anti–angiogenic glycodendrimers in a rabbit model of glaucoma surgery . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1053.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose:An in vivo study was undertaken in a well established rabbit model of glaucoma surgery and subconjunctival scarring to assess the effect of two novel synthetic glycodendrimers. A dendrimer is a hyperbranched synthetic polymer that has a multitude of peripheral endgroups that can be utilised for multivalent interactions. In vitro, dendrimer glucosamine (DG) reduced lipopolysaccharide induced release of pro–inflammatory chemokines (MIP–1α, MIP–1β and IL–8) and pro–inflammatory cytokines (TNFα, IL–1βand IL–6) from human macrophages and dendritic cells. Dendrimer glucosamine sulphate (DGS) displayed anti–angiogenic activity in 2 in vitro human model systems. DG and DGS were tested in combination in the rabbit model. Methods:Thirty New Zealand white rabbits underwent experimental glaucoma filtration surgery, as previously described by our group, with a fornix based conjunctival flap and a 22G venflon secured through a scleral tunnel. The rabbits were randomised to subconjunctival (sc) + intraperitoneal(ip) therapy, or to the carrier (sc + ip). The injections were given 2 days pre–operatively, on the operation day, and at intervals of 1–4 days post–operatively. The animals were observed post–operatively by a masked reader for 30 days. Bleb survival was the primary efficacy endpoint with failure defined as the appearance of a flat, scarred bleb with a deep anterior chamber. Results: The combination of DG and DGS significantly improved the success rate of the surgery 80% versus 30% survival (p=0.029) at day 30. No corneal, conjunctival or systemic toxicity was seen. Conclusions: Current treatments for the inflammatory response associated with glaucoma surgery are limited to steroids and immunosuppressants. Severe side–effects include cataract formation and infection. This combination of two novel dendrimer glycoconjugates offers new therapeutic opportunities for controlling excessive scar formation after eye surgery.

Keywords: wound healing • conjunctiva • immunomodulation/immunoregulation 
© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept